

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Brian Meltzer
Date of Last Notice:	22 nd December 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct														
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-														
Date of change	18 th September 2020														
No. of securities held prior to change	<table border="1" style="width: 100%;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: center;">-</td> <td style="text-align: center;">1,250,000</td> </tr> <tr> <td>Indirect</td> <td style="text-align: center;">326,666</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Total</td> <td style="text-align: center;">326,666</td> <td style="text-align: center;">1,250,000</td> </tr> </tbody> </table>				Shares	Options	Direct	-	1,250,000	Indirect	326,666	-	Total	326,666	1,250,000
	Shares	Options													
Direct	-	1,250,000													
Indirect	326,666	-													
Total	326,666	1,250,000													
Class	Unlisted Options														
Number acquired	<table border="1" style="width: 100%;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: center;">-</td> <td style="text-align: center;">7,000,000</td> </tr> <tr> <td>Indirect</td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Total</td> <td style="text-align: center;">-</td> <td style="text-align: center;">7,000,000</td> </tr> </tbody> </table>				Shares	Options	Direct	-	7,000,000	Indirect	-	-	Total	-	7,000,000
	Shares	Options													
Direct	-	7,000,000													
Indirect	-	-													
Total	-	7,000,000													

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	Shares	Options	
	Direct	-	-
	Indirect	-	-
	Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3 rd of September 2020.		
No. of securities held after change	Shares	Options	
	Direct	-	8,250,000
	Indirect	326,666	-
	Total	326,666	8,250,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of incentive options under ESOP		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



22 Dec 2012

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Dr. David Sinclair
Date of Last Notice:	8 th April 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct		
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-		
Date of change	18 th September 2020		
No. of securities held prior to change		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-
Class	Unlisted Options		
Number acquired		Shares	Options
	Direct	-	7,000,000
	Indirect	-	-
	Total	-	7,000,000

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	Shares	Options	
	Direct	-	-
	Indirect	-	-
	Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3 rd of September 2020.		
No. of securities held after change	Shares	Options	
	Direct	-	7,000,000
	Indirect	-	-
	Total	-	7,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of incentive options under ESOP		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



22 Dec 2012

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Geoffrey Kempler
Date of Last Notice:	22 nd December 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct														
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director related entity														
Date of change	18 th September 2020														
No. of securities held prior to change	<table border="1" style="width: 100%;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: right;">30,000</td> <td style="text-align: right;">5,000,000</td> </tr> <tr> <td>Indirect</td> <td style="text-align: right;">17,981,000</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Total</td> <td style="text-align: right;">18,011,000</td> <td style="text-align: right;">5,000,000</td> </tr> </tbody> </table>				Shares	Options	Direct	30,000	5,000,000	Indirect	17,981,000	-	Total	18,011,000	5,000,000
	Shares	Options													
Direct	30,000	5,000,000													
Indirect	17,981,000	-													
Total	18,011,000	5,000,000													
Class	Unlisted Options														
Number acquired	<table border="1" style="width: 100%;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: center;">-</td> <td style="text-align: right;">14,000,000</td> </tr> <tr> <td>Indirect</td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Total</td> <td style="text-align: center;">-</td> <td style="text-align: right;">14,000,000</td> </tr> </tbody> </table>				Shares	Options	Direct	-	14,000,000	Indirect	-	-	Total	-	14,000,000
	Shares	Options													
Direct	-	14,000,000													
Indirect	-	-													
Total	-	14,000,000													

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	Shares	Options	
	Direct	-	-
	Indirect	-	-
	Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3 rd of September 2020.		
No. of securities held after change	Shares	Options	
	Direct	30,000	19,000,000
	Indirect	17,981,000	-
	Total	18,011,000	19,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of incentive options under ESOP		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



22 December 2017

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Lawrence Gozlan
Date of Last Notice:	22 nd December 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct		
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-		
Date of change	18 th September 2020		
No. of securities held prior to change		Shares	Options
	Direct	-	1,250,000
	Indirect	-	-
	Total	-	1,250,000
Class	Unlisted Options		
Number acquired		Shares	Options
	Direct	-	7,000,000
	Indirect	-	-
	Total	-	7,000,000

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3 rd of September 2020.		
No. of securities held after change		Shares	Options
	Direct	-	8,250,000
	Indirect	-	-
	Total	-	8,250,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of incentive options under ESOP		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



22 Dec 2012

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Peter Marks
Date of Last Notice:	22 nd December 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct														
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-														
Date of change	18 th September 2020														
No. of securities held prior to change	<table border="1" style="width: 100%;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: center;">-</td> <td style="text-align: right;">1,250,000</td> </tr> <tr> <td>Indirect</td> <td style="text-align: right;">43,111</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Total</td> <td style="text-align: right;">43,111</td> <td style="text-align: right;">1,250,000</td> </tr> </tbody> </table>				Shares	Options	Direct	-	1,250,000	Indirect	43,111	-	Total	43,111	1,250,000
	Shares	Options													
Direct	-	1,250,000													
Indirect	43,111	-													
Total	43,111	1,250,000													
Class	Unlisted Options														
Number acquired	<table border="1" style="width: 100%;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: center;">-</td> <td style="text-align: right;">7,000,000</td> </tr> <tr> <td>Indirect</td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Total</td> <td style="text-align: center;">-</td> <td style="text-align: right;">7,000,000</td> </tr> </tbody> </table>				Shares	Options	Direct	-	7,000,000	Indirect	-	-	Total	-	7,000,000
	Shares	Options													
Direct	-	7,000,000													
Indirect	-	-													
Total	-	7,000,000													

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3 rd of September 2020.		
No. of securities held after change		Shares	Options
	Direct	-	8,250,000
	Indirect	43,111	-
	Total	43,111	8,250,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of incentive options under ESOP		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



22 Dec 2012

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Tristan Edwards
Date of Last Notice:	8 th April 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct		
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-		
Date of change	18 th September 2020		
No. of securities held prior to change		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-
Class	Unlisted Options		
Number acquired		Shares	Options
	Direct	-	7,000,000
	Indirect	-	-
	Total	-	7,000,000

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3 rd of September 2020.		
No. of securities held after change		Shares	Options
	Direct	-	7,000,000
	Indirect	-	-
	Total	-	7,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of incentive options under ESOP		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



22 Dec 2012

+ See chapter 19 for defined terms.